Immunovant, Inc.

NASDAQ:IMVT

Biotechnology

Healthcare
$33.21 +2.00%

+$0.69 today

Market cap
$6.87B
Beta
0.79
P/E (TTM)
-14.3
EPS (TTM)
-$2.48
52W Low $14.32High $36.29

Volume 0.93M

Average 1.84M

IMVT EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Immunovant, Inc.NASDAQ: IMVT

EBITDA · Q2 FY2027 · quarter ended Sep 2026

EBITDA remains negative

Q2 FY2027 EBITDA was -$97.16M, compared with -$125.8M a year earlier. Trailing-twelve-month EBITDA was -$509.88M.

Context

  • EBITDA grew in size in 3 of the last 3 fiscal years.
  • FY2026 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 9 analysts of $0 (+100.0%) for the fiscal year ending Mar 2027, a step up from the -22.4% reported in FY2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$97.16M+36.6% QoQ
Last fiscal yearMar 2026
-$504.98M-22.4% YoY
LTMSep 2026
-$509.88M-10.4% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+22.8%+100.0%+77.2 pp
1 year-22.4%+100.0%+122.4 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2026
(504.98M) USD
Year-over-year change
-22.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How IMVT compares with its peers on the latest reported figures

  • IMVT's LTM Sep 2026 EBITDA of -$509.88M is the lowest of the 11 companies compared; the peer median is -$137.86M.
  • Its year-over-year change of -10.4% is the 6th highest of 11, against a peer median of -12.7%.
  • EBITDA amounts to 7186.4% of revenue for IMVT, versus a peer median of 33.2%.
IMVT Competitors Peer median
EBITDA for IMVT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TGTXTG Therapeutics, Inc.LTM Sep 2026$191.33M +66.0%—21.3%
ANABAnaptysBio, Inc.LTM Mar 2026$58.49M +176.6%—25.2%
QTTBQ32 Bio Inc.LTM Mar 2026$22.15M +154.8%—41.2%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$70.61M -31.5%—843.9%
IMUXImmunic, Inc.LTM Mar 2026-$104.13M -8.2%——
CABACabaletta Bio, Inc.LTM Mar 2026-$171.58M -48.1%——
TRAXFirst Tracks Biotherapeutics IncFY2025-$178.45M +0.1%——
ANNXAnnexon, Inc.LTM Mar 2026-$193.41M -17.1%——
CGEMCullinan Therapeutics, Inc.LTM Mar 2026-$220.73M -23.8%——
ZBIOZenas BioPharma, Inc.LTM Mar 2026-$408.44M -151.5%——
IMVTImmunovant, Inc.LTM Sep 2026-$509.88M -10.4%—7186.4%
Peer median (excluding IMVT) -$137.86M-12.7%—33.2%

Competitors are the stored peer set for IMVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development101.81M160.26M212.93M360.92M456.66M
Selling, General & Admin54.23M48.02M57.28M77.24M76.24M
Operating Expenses156.03M208.28M270.21M438.15M532.9M
Depreciation & Amortization126K193K231K377K409K
EBITDA(156.69M)(198.28M)(258.54M)(412.57M)(504.98M)
EBITDA Margin—————
Operating Income(156.03M)(208.28M)(270.21M)(438.15M)(532.9M)
Operating Margin—————
Interest Income07.58M24.95M24.73M25.33M
Interest Expense012.48M000
Other Income / Expenses(781K)(2.68M)11.44M25.2M27.51M
Income Before Tax(156.81M)(210.95M)(258.77M)(412.95M)(505.39M)
Pre-Tax Margin—————
Income Tax Expense(84K)9K567K891K215K
Net Income(156.73M)(210.96M)(259.34M)(413.84M)(505.61M)
Net Margin—————
EPS (Basic)(1.43)(1.71)(1.88)(2.73)(2.77)
EPS (Diluted)(1.43)(1.71)(1.88)(2.73)(2.77)
Weighted Avg Shares109.68M123.08M138.1M151.57M182.42M
Weighted Avg Shares (Diluted)109.68M123.08M138.1M151.57M182.42M

Immunovant, Inc.

NASDAQ:IMVT

Intrinsic Alpha fair value

Locked

Current Price

$33.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.